Cargando…
Enhancement of Antitumor Immunity Using a DNA-Based Replicon Vaccine Derived from Semliki Forest Virus
A DNA-based replicon vaccine derived from Semliki Forest virus, PSVK-shFcG-GM/B7.1 ( Fig. 1a ) was designed for tumor immunotherapy as previously constructed. The expression of the fusion tumor antigen (survivin and hCGβ-CTP37) and adjuvant molecular protein (Granulocyte-Macrophage Colony-Stimulatin...
Autores principales: | Zhang, Liang, Wang, Yue, Xiao, Yi, Wang, Yu, Dong, JinKai, Gao, Kun, Gao, Yan, Wang, Xi, Zhang, Wei, Xu, YuanJi, Yan, JinQi, Yu, JiYun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946523/ https://www.ncbi.nlm.nih.gov/pubmed/24608380 http://dx.doi.org/10.1371/journal.pone.0090551 |
Ejemplares similares
-
Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors
por: Yu, YunZhou, et al.
Publicado: (2014) -
Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus
por: Ma, Jing, et al.
Publicado: (2021) -
Reconstitution of Semliki forest virus membrane
Publicado: (1977) -
Cholesterol is required for infection by Semliki Forest virus
Publicado: (1991) -
Membrane fusion mutants of Semliki Forest virus
Publicado: (1984)